GSK (GSK) to Release Earnings on Wednesday

GSK (NYSE:GSK) is projected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $7.75 billion for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

GSK Stock Performance

Shares of GSK stock opened at $35.12 on Wednesday. GSK has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm’s 50 day moving average price is $33.94 and its 200-day moving average price is $37.78. The firm has a market cap of $72.78 billion, a P/E ratio of 22.80, a P/E/G ratio of 1.31 and a beta of 0.63.

Analyst Upgrades and Downgrades

Several research firms have recently commented on GSK. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.